Unraveling Links Between Chronic Inflammation and Long COVID: Current State, Challenges, and Opportunities (Agenda)

Welcome and Introduction
Pushpa Tandon, Ph.D., National Cancer Institute

Keynote Speaker: Josh Fessel, M.D., Ph.D., National Center for Advancing Translational Sciences 

Update on Long COVID and post COVID research

Session 1: Diagnosing Long COVID and Identifying Risk Factors: Unresolved COVID or something more?

Chair: Gallya Gannot, D.M.D., Ph.D., National Center for Advancing Translational Sciences 

Amy Proal, Ph.D., PolyBio Research Foundation, Kenmore, WA

Sars-CoV-2 reservoir: potential driver of inflammation and other disease mechanisms in Long COVID/PASC

Melissa Haendel, Ph.D., University of Colorado Anschutz Medical Campus

Identifying who has Long COVID in the U.S.A.: a machine learning approach using N3C data

Saurabh Mehandru, M.D., Icahn School of Medicine at Mount Sinai

The Gastrointetinal Tract and Long COVID

Eleni Gavriilaki, M.D., Ph.D., Aristotle University of Thessaloniki, Greece

COVID-19 sequelae – Can long-term effects be predicted?

Panel Discussion

Moderators:
Preethi Chander, Ph.D., National Institute of Dental and Craniofacial Research 
Anju Singh, Ph.D., National Cancer Institute 

Session 2: Classifying Long COVID and Potential Mechanisms

Chair: Joy Liu, M.D., National Institute of Allergy and Infectious Diseases

Upinder Singh, M.D., Stanford University

Defining the pathophysiology of Long COVID / Long COVID Subtypes (using the RECOVER platform)

Julie McElrath, M.D., Ph.D., Fred Hutchinson Cancer Center

Immune memory of Long COVID

Joseph A. Bellanti, M.D., Georgetown University

Long COVID: A proposed hypothesis-driven model of viral persistence for the pathophysiology of the syndrome

Steven Z. Josefowicz, Ph.D., Cornell University

Epigenetic Memory of COVID-19 in innate immune cells and their progenitors

Panel Discussion

Moderators:
Mercy Prabhudas, Ph.D., National Institute of Allergy and Infectious Diseases
Leela Rani Avula, Ph.D., National Cancer Institute

Day 1 Wrap Up
Gallya Gannot, D.M.D., Ph.D., National Center for Advancing Translational Sciences

Review from Day 1: Goals and Objectives
Merriline Satyamitra, Ph.D., National Institute of Allergy and Infectious Diseases

Keynote Speaker: Richard C. Becker, M.D., University of Cincinnati

Organ-Specific Inflammation and Long-COVID

Session 3: Neurological Effects

Chair: Danielle Carrick, Ph.D. M.H.S., National Cancer Institute

Prof. Raimund Helbok, M.D., Ph.D., Department of Neurology, Johannes Kepler University Linz, Linz, Austria

Covid 19: challenges for Neurology

Avindra Nath, M.D., National Institute of Neurological Disorders and Stroke

Neuropathogenesis of Long-COVID

Anne Louise Oaklander, M.D., Ph.D., Massachusetts General Hospital

Post-infectious peripheral neuropathy in Long COVID – mechanisms, diagnosis and mitigation

Prof. Theoharis Theoharides, MSc, Ph.D., M.D., Nova Southeastern University

SARS-CoV-2 spike protein, neuroinflammation and brain fog

Panel Discussion

Moderators:
Nataliya Gordiyenko, Ph.D., National Eye Institute
Christina Liu, Ph.D., P.E., National Institute of General Medical Sciences

Session 4: Cardiovascular, Respiratory, and Immunological Effects 

Chair: Rao L. Divi, Ph.D., National Cancer Institute

Jim Morrissey, Ph.D., University of Michigan

COVID-19 Associated Coagulopathy (C.A.C.)

James Harker, Ph.D., Imperial College London, London, UK

Immuno-proteomics of the post-COVID19 lung and its link to pathology

James Stone, M.D., Ph.D., Massachusetts General Hospital

Cardiac Pathology in Long-COVID

Colin Berry, M.D., Ph.D., University of Glasgow, UK

Prevention and early treatment of the long-term physical effects of COVID-19: a randomised clinical trial of resistance exercise

Panel Discussion

Moderators:
Natalie Abrams, Ph.D., National Cancer Institute
Ronald Warren, Ph.D., National Heart, Lung, and Blood Institute

Keynote Speaker: Edward Conway, M.D., Ph.D., University of British Columbia

The ins and the outs, the long and the short, of complement in COVID-19

Session 5: Comorbidities and Long COVID - What do these chronic inflammatory conditions mean for Long COVID

Chair: Mulualem E. Tilahun, D.V.M., Ph.D., National Institute of Aging

Shabnam Salimi, M.D., University of Maryland

What does aging mean for Long COVID effects

Divaker Choubey, Ph.D., University of Cincinnati

Autoimmune diseases and Long COVID

Charisse Madlock-Brown, Ph.D., University of Iowa

Long COVID, selection criteria, and representation

Charis Bridger Staatz, Ph.D., University College London

Age of first developing overweight or obesity, COVID-19 and Long COVID in two British birth cohorts

Panel Discussion

Moderators:
Joy Liu, M.D., National Institute of Allergy and Infectious Diseases
Chiayeng Wang, Ph.D., National Cancer Institute 

Session 6: Prevention and Treatment

Chair: Johanna Dwyer, D.Sc. R.D., National Institutes of Health, Office of Dietary Supplements

Dhruv Khullar, M.D., Cornell University

Disparities in Post-Acute Sequelae of COVID-19 (Long COVID)

Linda C. Geng, M.D., Ph.D., Stanford University

Long COVID and Viral Persistence: Exploring Avenues for Therapies

Amy Arnsten, Ph.D., Yale University

Clinical experience with the α2A-adrenoceptor agonist, guanfacine, and N-acetylcysteine for the treatment of cognitive deficits in Long COVID 

Panel Discussion

Moderators:
Rao L. Divi, Ph.D., National Cancer Institute 
Christina Liu, Ph.D. P.E., National Institute of General Medical Sciences